Aptevo Therapeutics Inc. — Investor Relations & Filings
Filings indexed
683
across all filing types
Latest filing
2026-05-06
Regulatory Filings
Country
US
United States of America
Listing
US
APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company specializes in creating bispecific and trispecific antibody-based therapeutics designed to harness a patient's immune system to fight malignancies. Its pipeline includes multiple candidates targeting both hematologic cancers and solid tumors. The lead candidate, Mipletamig, is a CD3 T-cell engager targeting the CD123 tumor antigen for the treatment of Acute Myeloid Leukemia (AML). Other programs in development target various tumor antigens, including PSMA for prostate cancer and Nectin-4 for solid tumors, utilizing mechanisms like T-cell engagement and co-stimulation to enhance anti-tumor activity.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Aptevo Therapeutics Inc. (0001671584) (Filer) | 2026-05-06 | English | |
| Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment | 2026-03-27 | English | |
| 8-K - APTEVO THERAPEUTICS INC. (0001671584) (Filer) | 2026-02-19 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| 8-K Filing | 2026-02-03 | English |
Browse filings by year
11 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 42001589 | 8-K - Aptevo Therapeutics Inc. (0001671584) (Filer) | 2026-05-06 | English | ||
| 33062838 | Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment | 2026-03-27 | English | ||
| 32896295 | 8-K - APTEVO THERAPEUTICS INC. (0001671584) (Filer) | 2026-02-19 | English | ||
| 31224528 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31224515 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31224508 | 8-K Filing | 2026-02-03 | English | ||
| 31224455 | 424B4 Filing | 2026-01-30 | English | ||
| 31224522 | S-1 Filing | 2026-01-28 | English | ||
| 31224517 | DEF 14A Filing | 2026-01-26 | English | ||
| 12947011 | PRE 14A | 2026-01-16 | English | ||
| 12947014 | 8-K | 2026-01-09 | English | ||
|
2025
4 filings
| |||||
| 12947015 | 8-K | 2025-12-29 | English | ||
| 12947016 | 8-K | 2025-12-09 | English | ||
| 12947017 | Regulatory Filings 2025 | 2025-11-26 | English | ||
| 12947019 | 424B4 | 2025-11-25 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
ACROBIOSYSTEMS CO.,LTD.
Provides recombinant proteins and reagents for life science…
|
301080 | CN | Professional, scientific and te… |
|
ACTINOGEN MEDICAL LIMITED
Developing cortisol-inhibiting therapies for Alzheimer's an…
|
ACW | AU | Professional, scientific and te… |
|
Active Biotech
Biotechnology company developing drugs for oncology and inf…
|
ACTI | SE | Professional, scientific and te… |
|
Adagene Inc.
Clinical-stage biotech developing antibody-based immunother…
|
ADAG | KY | Professional, scientific and te… |
|
ADALTA LIMITED
Clinical-stage biotech developing i-body protein therapeuti…
|
1AD | AU | Professional, scientific and te… |
|
Adaptive Biotechnologies Corp
Decodes the adaptive immune system to develop products for …
|
ADPT | US | Professional, scientific and te… |
|
Adeia Inc.
R&D company that licenses IP for the media, entertainment, …
|
ADEA | US | Professional, scientific and te… |
|
Aditxt, Inc.
Acquires, develops, and deploys health technologies to addr…
|
ADTX | US | Professional, scientific and te… |
|
Advanced Biomed Inc.
Develops microfluidic biochip diagnostic systems for precis…
|
ADVB | US | Professional, scientific and te… |
|
Advanced Proteome Therapeutics Corporation
Develops proprietary technology for chemical modification o…
|
APC.H | CA | Professional, scientific and te… |
Aptevo Therapeutics Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35422/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35422 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35422 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35422 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35422}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Aptevo Therapeutics Inc. (id: 35422)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.